Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. A number ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in t ...

Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...

Dynavax Technologies (DVAX) closed the last trading session at $13.33, gaining 4.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new ...

Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...

Dynavax Technologies (NASDAQ:DVAX) rose 2.8% after a large investor started a proxy fight with the vaccine maker. Deep Track ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...

Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NAS ...